PF pathogenesis involves alveolar epithelial cell injury, profibrotic mediators, and dysregulated non-coding RNAs, complicating disease management. Current treatments, including pirfenidone and ...

The field of PPF is moving towards a personalized, data-driven approach, emphasizing biomarker integration and risk stratification for early diagnosis and treatment. Recent guidelines standardized PPF ...

Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.

Preclinical data indicate that inhaled treprostinil may be useful for the treatment of idiopathic pulmonary fibrosis (IPF) through an antifibrotic mechanism, a premise that is supported by clinical ...

Preclinical data demonstrate ATYR0101’s unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 ...

Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior ...